Difficulty: Medium
Average Score: 84%
Practice
Chronic long-term therapy of myasthenia is usually accomplished with:
Correct answer
B
Rationale
In the treatment of myasthenia gravis, a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, long-term therapy typically involves the use of cholinesterase inhibitors like neostigmine (Option B). Neostigmine works by inhibiting the enzyme acetylcholinesterase, thereby increasing the levels of acetylcholine at the neuromuscular junction and improving muscle function.
Option A, Edrophonium, is a short-acting cholinesterase inhibitor used for diagnostic purposes in myasthenia gravis but is not suitable for long-term therapy due to its short duration of action.
Option C, Echothiophate, is an irreversible cholinesterase inhibitor primarily used for the treatment of glaucoma, not myasthenia gravis.
Option D, Carbachol, is a non-selective cholinergic agonist used for conditions like glaucoma and intraocular hypertension, but it is not typically used for the chronic management of myasthenia gravis.
Educationally, understanding the appropriate pharmacological management of myasthenia gravis is crucial for healthcare professionals, especially nurses and pharmacists, who may be involved in the care of patients with this condition. Knowing the mechanism of action of medications like neostigmine and their appropriate use in chronic therapy is essential for optimizing patient outcomes and quality of life.
Option A, Edrophonium, is a short-acting cholinesterase inhibitor used for diagnostic purposes in myasthenia gravis but is not suitable for long-term therapy due to its short duration of action.
Option C, Echothiophate, is an irreversible cholinesterase inhibitor primarily used for the treatment of glaucoma, not myasthenia gravis.
Option D, Carbachol, is a non-selective cholinergic agonist used for conditions like glaucoma and intraocular hypertension, but it is not typically used for the chronic management of myasthenia gravis.
Educationally, understanding the appropriate pharmacological management of myasthenia gravis is crucial for healthcare professionals, especially nurses and pharmacists, who may be involved in the care of patients with this condition. Knowing the mechanism of action of medications like neostigmine and their appropriate use in chronic therapy is essential for optimizing patient outcomes and quality of life.